Literature DB >> 3569847

Effects of ketamine on nociception and gastrointestinal motility in mice are unaffected by naloxone.

R N Takahashi, G S Morato, G A Rae.   

Abstract

The present study investigates the effects of ketamine on nociception towards chemical and thermic stimuli and on gastrointestinal transit in mice. The reversibility of these effects by the opioid antagonist naloxone (10 mg/kg) was also assessed. Ketamine promoted dose-related analgesia in both the acetic acid-induced writhing and hot plate tests. Analgesia was not influenced by pretreatment with naloxone. Contrasting the constipation induced by opioids, ketamine enhanced gastrointestinal transit in a dose-dependent manner and this was not modified by naloxone. These results suggest that although ketamine can elicit analgesia, it does not activate opioid mechanisms in subanesthetic doses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569847     DOI: 10.1016/0306-3623(87)90251-5

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

2.  The effects of perioperative analgesia on litter size in Crl:CD1(ICR) mice undergoing embryo transfer.

Authors:  David R Goulding; Page H Myers; Eugenia H Goulding; Terry L Blankenship; Mary F Grant; Diane B Forsythe
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-07       Impact factor: 1.232

3.  Prophylactic Ketamine Attenuates Learned Fear.

Authors:  Josephine C McGowan; Christina T LaGamma; Sean C Lim; Melina Tsitsiklis; Yuval Neria; Rebecca A Brachman; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2017-01-27       Impact factor: 7.853

4.  Effects of intravenous ketamine on gastrointestinal motility in the dog.

Authors:  J Fass; R Bares; V Hermsdorf; V Schumpelick
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.